Table 4.
Results of subgroup meta- analyses for Campylobacter and irritable bowel syndrome from studies published prior to July 2011
| Variable | Summary Estimate | Lower 95% CI | Upper 95% CI | I 2 | Number of outcome measures |
|---|---|---|---|---|---|
| Overall Estimate | 4.01% | 1.41% | 10.88% | 99.2% | 10 |
| Study Directionality | |||||
| Prospective | 8.64% | 6.36% | 11.66% | 83.7% | 8 |
| Retrospective | 0.15% | 0.0048% | 4.75% | 99.4 | 2 |
| Method of Assessing Sequelae | |||||
| Self-reported | 5.27% | 0.84% | 26.84% | 68.0% | 2 |
| Self-reported based on validated scale* | 9.94% | 7.90% | 12.44% | 73.6% | 6 |
| Based on medical records | 0.15% | 0.0048% | 4.75% | 99.4% | 2 |
| Group Size | |||||
| Small | 13.56% | 5.76% | 28.74% | 0.0% | 2 |
| Medium | 4.96% | 1.43% | 15.79% | 91.2% | 2 |
| Large | 9.92% | 7.52% | 12.98% | 83.6% | 4 |
| Extra large | 0.15% | 0.0048% | 4.75% | 99.4 | 2 |
*Questionnaires using self-reported responses to Rome I/Rome II criteria.